Annexin Pharmaceuticals AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.annexinpharma.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Annexin Pharmaceuticals AB
- Target Recruit Count
- 16
- Registration Number
- NCT05532735
- Locations
- 🇺🇸
Eye Associates of Northeast Louisiana, West Monroe, Louisiana, United States
🇺🇸Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸Tulsa Retina Consultants, Tulsa, Oklahoma, United States
First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Annexin Pharmaceuticals AB
- Target Recruit Count
- 46
- Registration Number
- NCT04850339
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
News
No news found